Dharmesh Patel, Ph.D’s Post

𝗘𝗻𝗵𝗮𝗻𝗰𝗶𝗻𝗴 𝗵𝗶𝗣𝗦𝗖-𝗖𝗠 𝗺𝗮𝘁𝘂𝗿𝗮𝘁𝗶𝗼𝗻 𝘄𝗶𝘁𝗵 𝗧𝟯 𝗮𝗻𝗱 𝗗𝗲𝘅: 𝗔 𝗺𝘂𝗹𝘁𝗶𝗽𝗹𝗲𝘅 𝗮𝗽𝗽𝗿𝗼𝗮𝗰𝗵 🫀✨ Are you working with hiPSC-derived cardiomyocytes (hiPSC-CMs) and looking to improve their maturation for applications in disease modeling, drug discovery, or cell therapy? We've got something exciting to share with you! In collaboration with Bayer, Fraunhofer IBMT, and Hamamatsu Photonics France, we've developed an application note that dives into how triiodothyronine (T3) and dexamethasone (Dex) can enhance the structural and functional maturation of hiPSC-CMs. Our study combines impedance/EFP and calcium imaging to track calcium transients and electrical activity in the same cells. The results are promising, T3 and Dex not only modulate the electrical activity but also improve calcium handling, crucial for the maturation of these cells. We also explored how the NSP-96 transparent plate can be used for multiple assays, allowing you to measure electrical activity, contractility, and calcium transients from the same cell population using the CardioExcyte 96 and FDSS/μCELL. This means more data from fewer cells and reduced variability. Curious to learn more? Check out the full application note here: https://ow.ly/bwVS50T1NC4 #Cardiomyocytes #hiPSC #StemCells #DrugDiscovery #CellAnalytics #CardioExcyte96

1. Researchers from the University of Cincinnati developed a new method to accelerate drug discovery, aiming to shorten the timeline from years to months. 2. The study was published in Science Advances on August 30. 3. The method combines data from the LINCS database and targeted docking simulations to identify potential drugs. 4. This approach significantly reduces screening time from weeks to just an afternoon. 5. The new method is not only faster but also more efficient in identifying effective compounds. 6. It offers hope for treatments of diseases with no known cures, including cancer. 7. The accelerated process could enhance responses to public health crises, like the COVID-19 pandemic. 8. The study emphasizes the potential for more targeted treatment options in precision medicine.

Our AI Breakthrough in Antiviral Discovery Now Published! I'm excited to share that our latest research has been published in Antiviral Research! This work presents Cortex Discovery AI platform, and shows how the use of its virtual high-throughput screening (HTS) and virtual ADMET capabilities, has led to efficient drug discovery. Out of 6 compounds tested, 5 showed efficacy against SARS-CoV-2 in infected cells, with 2 now patented working prior and after COVID infection in 3D human cell cultures. Special thanks to Demi van der Horst, PhD and David Olagnier from Aarhus University for their outstanding work on the experiments and to our funders, notably CNRS, Novonordiskfonden and Lundbeckfonden. https://lnkd.in/dhkgTT2E Follow us for updated news in the AI-driven development of novel longevity compounds! #CortexDiscovery #AI #COVID #SARSCoV2 #AntiviralResearch #DrugDiscovery #VirtualHTS #VirtualADMET #Innovation #Patents #AarhusUniversity #CNRS

Really excited to share our latest preprint via a #KeedyLab / Advanced Science Research Center, GC/CUNY collaboration with the #FarooqiLab / University of Cambridge. We investigated whether structural characterization of human #PTP1B variant proteins might reveal precise mechanisms to target for weight loss therapy. 12 rare PTP1B variants were selected for functional characterization from exomes from 997 people with persistent thinness and 200,000 people from UK Biobank. Seven of 12 variants impaired PTP1B function by increasing leptin-stimulated #STAT3 phosphorylation in cells. Using room-temperature X-ray #crystallography, hydrogen-deuterium exchange mass spectrometry (#HDX), and computational modeling, we determined that human variants modulate the 3-dimensional structure of PTP1B through distinct #allosteric conduits that energetically link distal, highly ligandable structural regions to the active site. Our study highlights the value of coupling human genetics and structural biophysics for targeted drug discovery, and hope to use these studies as a foothold to inform the design of allosteric PTP1B #inhibitors for the treatment of obesity. Check it out right here!

𝐑𝐚𝐢𝐬𝐢𝐧𝐠 𝐭𝐡𝐞 𝐒𝐭𝐚𝐧𝐝𝐚𝐫𝐝 𝐢𝐧 𝐀𝐧𝐭𝐢𝐛𝐨𝐝𝐲 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 This recent paper by Richard Kahn on antibody characterization highlights a critical challenge in biomedical research. At Cell Surface Bio, we’re tackling this by producing only recombinant antibodies and rigorously testing each one for off-target effects. We also test every antibody for applications like flow cytometry and immunofluorescence. If we say an antibody is validated for an application, we’ll show you the data to back it up!   We believe that with better tools, comes better science. Let’s work together to elevate the standards in antibody research and drive reproducibility across the field. 🌟🔬   https://lnkd.in/eRA-_E-F https://lnkd.in/e6HkuSPk #Biotech #Antibodies #Reproducibility #Innovation

The pioneering work by the University of Wisconsin–Madison, enabling cells to be programmed for specific molecular organization, heralds a transformative era for biotechnology and CROs like ourselves. This breakthrough offers optmised control over cellular behavior, potentially revolutionising how new treatments are developed. By manipulating proteins within cells to follow designated paths, researchers can now orchestrate complex cellular functions, a leap forward in understanding and treating diseases like cancer. For the biotech industry, this means the creation of more targeted therapies with fewer side effects, significantly impacting drug discovery and development processes. CROs, pivotal in bridging innovative research and clinical applications, might see a surge in demand for bioinformatics services, as the industry seeks to leverage this tool for therapeutic innovation. This advancement underscores a future where bioinformatics and cellular engineering converge to unlock new medical treatments. #CellularEngineering #Bioinformatics #BiotechInnovation #MolecularBiology #DrugDiscovery #ProteinOrganization #MedicalResearch #TherapeuticInnovation #CancerResearch See the work here: https://lnkd.in/epGVDrpw

¿What is In vivo and in vitro experiments?🔍 🌐✨ COLLABORATION IN ACTION! ✨🌐 At Moldrug, we believe in the power of collaboration to achieve excellence in research and development. We work closely with various companies, universities, and research institutions with extensive experience in preclinical and toxicological studies. 🤝🔬 Our network of collaborators spans in vitro studies with cell or tissue models, protein expression and purification, in vivo assays with animal models, and ecotoxicological assays, among others. 🧬 This collaboration allows us to complement our computational studies with experimental analyses for toxicity assessment, interaction confirmation, transcriptomics or genomic analysis, cellular screening, and more! 💡 The combination of computational and experimental approaches positions us at the forefront of research. Together, we advance towards innovative discoveries! #Moldrug #ScientificCollaboration #InnovativeResearch #ScienceAndTechnology #TeamworkInAction

Quantum computing is revolutionizing pharmaceuticals by offering unparalleled computational power to model complex molecular interactions. This technology expedites the discovery of new treatments for diseases like cancer and Alzheimer's by rapidly screening and optimizing drug compounds. Embracing quantum computing in drug discovery not only speeds up the process but also enhances the precision of predictions, paving the way for personalized medicine. #QuantumComputing #HealthcareTechnology

I am thrilled to share a publication in Cell Reports, titled "Human antibody polyreactivity is governed primarily by the heavy-chain complementarity-determining regions," in collaboration with the esteemed Prof. Peter Tessier and a fantastic team of researchers. Key Highlights: - Polyreactivity Insights: the study reveals that human antibody polyreactivity is predominantly mediated by the heavy-chain complementarity-determining regions (CDRs), characterized by high positive charge and hydrophobicity. - Machine Learning Model: a robust model was developed to predict antibody polyreactivity. It leverages key molecular features and has been validated against the largest and most diverse antibody datasets reported to date. - Broad Applications: The findings have significant implications for antibody-drug design, potentially guiding the development of antibodies with optimized specificity and reduced non-specific interactions. Take Home Message: Understanding the molecular basis of antibody polyreactivity can revolutionize the design and development of therapeutic antibodies, enhancing their efficacy and safety. The newly-introduced machine learning model offers a powerful tool for predicting and minimizing polyreactivity, paving the way for more effective antibody-based therapies. A huge thank you to Prof. Peter Tessier and the research team for including my contribution in this work. Full paper here: https://lnkd.in/e2YsBPnD #Research #Antibodies #Polyreactivity #MachineLearning #Biotechnology #CellReports

Our newly published research titled “Characterization of Limbal Mesenchymal Stromal Cell Subpopulations: Insights into Ocular Surface Repair and Regeneration”sheds light on the diverse subpopulations of Limbal Mesenchymal Stromal Cells (LMSCs) and their crucial roles in ocular surface repair and regeneration. This study explores the dynamic expression of markers related to #MSCs, #woundhealing, #immuneregulation, and #differentiation during in vitro expansion, providing valuable insights for advancing #regenerativetherapies for ocular surface disorders. Discover how these findings can inform standardized protocols and improve treatment outcomes! You can read the full article here: https://lnkd.in/dN_NRHMQ